Even so, the complex vaccine will be expensive by developing world standards, and its cost - effectiveness is a major issue
for vaccine developers and public health experts, says Scott Filler of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
That could be a serious concern
for vaccine developers, says John LaMontagne, director of the division of Microbiology and Infectious Disease at the National Institute of Allergy and Infectious Diseases.
Not exact matches
Vaccine developers for these diseases will probably also have to look in unusual places
for answers.
Vaccine developers are trying to improve vaccines for transplant recipients and other people with a weak immune system, and the samples used in this study came from a clinical trial of different versions of a flu vaccine in patients on immune - suppressive
Vaccine developers are trying to improve
vaccines for transplant recipients and other people with a weak immune system, and the samples used in this study came from a clinical trial of different versions of a flu
vaccine in patients on immune - suppressive
vaccine in patients on immune - suppressive drugs.
Now, Modhiran et al. and Beatty et al. describe the results of in vitro and in vivo experiments that point to circulating dengue virus non-structural protein 1 (NS1) and the innate immune Toll - like receptor 4 (TLR4) as a focus
for basic scientists as well as
vaccine and drug
developers.
Currently, there are three phase - three clinical trials
for a dengue
vaccine and UNC is collaborating with
vaccine developers to understand data from these trials, de Silva said.
«Currently, there are three phase - three clinical trials
for a dengue
vaccine and UNC is collaborating with
vaccine developers to understand data from these trials.»